antifungal therapy – Page 4

ABPA in post-tuberculosis lung disease: A diagnostic pitfall or genuine entity?

mycolabadmin

This article addresses confusion between two Aspergillus lung infections that commonly occur after tuberculosis: ABPA and CPA. While they have overlapping symptoms and test results, they require different treatments—ABPA responds to short-term steroids while CPA needs prolonged antifungal drugs. Importantly, giving steroids for misdiagnosed CPA can be harmful, so doctors should be cautious about diagnosing ABPA in tuberculosis survivors and consider CPA instead.

A case of Blastomyces helicus pneumonia in a dog from a non-endemic region: diagnostic challenges and successful treatment outcome

mycolabadmin

A dog from Colorado developed a severe respiratory infection that was initially mistaken for a bacterial pneumonia. After antibiotics failed to help, advanced testing revealed the dog had a fungal infection caused by Blastomyces helicus, a rare fungus found in western North America. The dog was successfully treated with an antifungal medication called itraconazole and made a complete recovery within six months, demonstrating the importance of considering fungal infections when standard treatments fail.

Allergic bronchopulmonary mycosis caused by Scedosporium apiospermum: A case report

mycolabadmin

A 61-year-old woman developed a rare fungal infection in her lungs caused by Scedosporium apiospermum while undergoing cancer treatment. The infection caused persistent cough, mucus plugs in the airways, and high levels of immune cells called eosinophils. Doctors used genetic testing to identify the specific fungus and then treated her with corticosteroids and antifungal medications, which improved her condition significantly.

A human-relevant alternative infection model for mucormycosis using the silkworm Bombyx mori

mycolabadmin

Researchers developed a silkworm-based model to study mucormycosis, a deadly fungal infection. The model reproduces the same disease patterns and risk factors seen in humans, including effects of steroids and iron levels. Importantly, it successfully predicted how well antifungal drugs work against the infection, offering a faster and more ethical alternative to mammal testing for developing new treatments.

Continuous debridement combined with short-term posaconazole therapy for cutaneous mucormycosis caused by Rhizopus oryzae infection secondary to acute myeloid leukemia: a case report

mycolabadmin

An 80-year-old patient with acute myeloid leukemia developed a serious fungal skin infection caused by Rhizopus oryzae on his lower leg. Doctors treated the infection by repeatedly cleaning out the infected tissue and giving him an antifungal medication called posaconazole for just one week. Despite the short treatment duration due to cost concerns, the patient’s wound gradually healed over four months through continued surgical care, showing that sometimes focused surgical treatment can be as effective as long-term medication.

First human case of Eidernor doerrieniae colonization in a peritoneal dialysis catheter: A warning from silent contamination

mycolabadmin

A 52-year-old dialysis patient noticed brownish particles inside his peritoneal dialysis catheter. Doctors identified a rare fungus called Eidernor doerrieniae using DNA sequencing, which had never been found in humans before. The catheter was removed and the patient received antifungal medications that successfully eliminated the infection without causing serious complications.

A Case Report of Candidiasis Cellulitis in Long-Term Corticosteroid Use

mycolabadmin

A 54-year-old man developed a serious skin infection on his hand caused by Candida, a normally harmless fungus, because he had been taking corticosteroid injections for 15 years for breathing problems. Despite antibiotic treatment, the swelling and pain continued. Doctors discovered it was a fungal infection through lab tests and treated it with antifungal medication (fluconazole) after draining the infection, which completely healed within two weeks.

Detection and diagnostic process of liver abscess secondary to chemotherapy by mucor indicus in a patient with acute leukemic disease: case report

mycolabadmin

A 60-year-old man with acute leukemia developed a serious fungal infection in his liver caused by Mucor indicus after receiving chemotherapy that weakened his immune system. Doctors identified the infection through tissue samples and genetic testing, then treated him successfully with antifungal medications amphotericin B and posaconazole. This case highlights the importance of early detection and proper diagnosis of rare fungal infections in cancer patients undergoing chemotherapy.

Fungal Infections – a Stealthy Enemy in Patients with Chronic Granulomatous Disease: a 28-years’ Experience from North India

mycolabadmin

Patients with chronic granulomatous disease (CGD), a rare immune system disorder, are highly susceptible to serious fungal infections. This study of 99 patients over 28 years found that 40% developed fungal infections, mostly caused by Aspergillus fungi affecting the lungs. These infections were life-threatening, with over half the infected patients dying despite aggressive treatment with antifungal medications. Doctors need to screen for fungal infections early, even in patients without obvious symptoms, and treat infants and males more aggressively.

Brazilian task force for the management of mucormycosis

mycolabadmin

Mucormycosis is a serious fungal infection that has become more common in Brazil, especially during COVID-19. This medical emergency requires rapid diagnosis through imaging and tissue sampling, combined with aggressive treatment including antifungal medications and surgery to remove infected tissue. The Brazilian government has made these powerful antifungal drugs more available to improve patient survival and reduce the severe complications of this dangerous infection.

Research Keyword: antifungal therapy